Physician profile
Mark Leekoff
NPI 1598183311
$132,660.44
in general payments reported to CMS, 2019-2025
33 companies · $70K in 2025
The $70K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.11 · 2020: $1,840 · 2021: $574 · 2022: $4,264 · 2023: $16K · 2024: $40K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Travel and Lodging: $18K · Food and Beverage: $15K · Consulting Fee: $13K · Honoraria: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,960.00 |
| Travel and Lodging | $18,185.77 |
| Food and Beverage | $15,310.57 |
| Consulting Fee | $13,265.00 |
| Honoraria | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $57,335.60 | 2023-2025 | |
| Amgen INC. | $25,504.81 | 2024-2025 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $18,718.69 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $9,810.64 | 2020-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Celgene Corporation | $9,676.69 | 2022-2025 | Zeposia |
| Horizon Therapeutics Plc | $3,459.43 | 2022-2023 | Uplizna |
| Biogen, INC. | $2,511.55 | 2019-2025 | Tysabri, Vumerity |
| Genentech, INC. | $2,263.29 | 2021-2025 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $1,133.47 | 2022-2025 | |
| Emd Serono, INC. | $912.70 | 2024-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $217.45 | 2024-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $140.46 | 2023-2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $139.60 | 2025 | Symbravo, Sunosi |
| Vanda Pharmaceuticals INC. | $139.16 | 2024-2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $123.25 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $77.54 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $70.49 | 2024-2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $55.85 | 2023-2024 | Synchromedii, Percept PC Brainsense |
| Novo Nordisk INC | $40.27 | 2025 | Ozempic, Rybelsus |
| Janssen Biotech, INC. | $35.19 | 2024-2025 | Tremfya |
| Kyowa Kirin, INC. | $35.00 | 2024 | Nourianz |
| Mallinckrodt Hospital Products INC. | $34.80 | 2024-2025 | Acthar |
| Pfizer INC. | $33.80 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $33.41 | 2025 | Tascenso Odt, Bafiertam |
| Genzyme Corporation | $23.82 | 2025 | |
| Lilly USA, LLC | $18.46 | 2024 | Taltz |
| Merz Pharmaceuticals, LLC | $17.74 | 2024 | Ampyra |
| Almatica Pharma LLC | $17.65 | 2022 | |
| Argenx US, INC. | $17.56 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Azurity Pharmaceuticals, INC. | $17.20 | 2024 | Horizant |
| Grifols USA, LLC | $16.98 | 2025 | Xembify |
| Sk Life Science, INC. | $15.11 | 2024 | |
| Boston Scientific Corporation | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Leekoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.